{"id":611793,"date":"2022-08-12T18:52:01","date_gmt":"2022-08-12T18:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=611793"},"modified":"2022-08-12T18:52:01","modified_gmt":"2022-08-12T18:52:01","slug":"hyperkalemia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-ardelyx-vifor-pharma-astrazeneca-zeria-pharmaceutical-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hyperkalemia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-ardelyx-vifor-pharma-astrazeneca-zeria-pharmaceutical-and-others_611793.html","title":{"rendered":"Hyperkalemia Market to Register Sustainable Growth During the Forecast Period &#8211; DelveInsight | Key Companies &#8211; Ardelyx, Vifor Pharma, AstraZeneca, Zeria Pharmaceutical, and others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hyperkalemia Market to Register Sustainable Growth During the Forecast Period - DelveInsight | Key Companies - Ardelyx, Vifor Pharma, AstraZeneca, Zeria Pharmaceutical, and others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Hyperkalemia Market to Register Sustainable Growth During the Forecast Period - DelveInsight | Key Companies - Ardelyx, Vifor Pharma, AstraZeneca, Zeria Pharmaceutical, and others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong>Hyperkalemia Market<\/strong>&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalemia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Hyperkalemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/13fa2e83ddd8b06b99391110789af9d4.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hyperkalemia: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Hyperkalemia is defined as a high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.<\/p>\n<p style=\"text-align: justify;\"><em>Risk factors for hyperkalemia include several conditions such as chronic kidney disease, diabetes, congestive heart failure and certain medications that disrupt the potassium balance. Also, males are found to suffer more than females with Hyperkalemia.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hyperkalemia Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>According to the National Kidney Foundation, the prevalence and incidence of Hyperkalemia have been estimated to be <strong>2-3%<\/strong> in the general population and about <strong>1-10%<\/strong> among hospitalized patients. People with chronic kidney disease, heart failure, diabetes mellitus, and those taking blood pressure medicines (RAASi) have an estimated <strong>2&ndash;3 times<\/strong> higher risk for hyperkalemia. More than half of pre-dialysis CKD patients are at risk of developing Hyperkalemia.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>In a study conducted by Betts et al. (2018), it was estimated that the annual prevalence of hyperkalemia was <strong>1.57%<\/strong> in 2014, with higher rates observed in patients with chronic kidney disease (CKD), heart failure, diabetes, and hypertension. Among patients with CKD and\/or heart failure, the 2014 annual prevalence was <strong>6.35%<\/strong>.<\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hyperkalemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Hyperkalemia Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Hyperkalemia market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Hyperkalemia market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hyperkalemia Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hyperkalemia Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Hyperkalemia market<\/strong> or expected to get launched during the study period. The analysis covers Hyperkalemia market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Hyperkalemia Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key players in the Hyperkalemia market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ardelyx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Vifor Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Zeria Pharmaceutical<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Hyperkalemia Therapies Covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Veltassa<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lokelma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">RDX013<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Hyperkalemia Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Hyperkalemia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Hyperkalemia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Hyperkalemia Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Hyperkalemia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Hyperkalemia Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Hyperkalemia Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Hyperkalemia Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Hyperkalemia Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Hyperkalemia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Hyperkalemia Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Hyperkalemia Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Hyperkalemia Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Hyperkalemia Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Hyperkalemia Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Hyperkalemia Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/hyperkalemia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Report by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/subarachnoid-hemorrhage-market\">Subarachnoid Hemorrhage Market<br \/><\/a><\/strong>&ldquo;Subarachnoid Hemorrhage Market&rdquo; research report provides a detailed overview of the historical and forecasted epidemiology as well as the Subarachnoid Hemorrhage Market size, share, and trends in the 7MM. Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the Subarachnoid Hemorrhage therapeutics Market.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hyperkalemia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-ardelyx-vifor-pharma-astrazeneca-zeria-pharmaceutical-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hyperkalemia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-ardelyx-vifor-pharma-astrazeneca-zeria-pharmaceutical-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Hyperkalemia Market&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalemia Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hyperkalemia-market-to-register-sustainable-growth-during-the-forecast-period-delveinsight-key-companies-ardelyx-vifor-pharma-astrazeneca-zeria-pharmaceutical-and-others_611793.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,417,406,404],"tags":[],"class_list":["post-611793","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=611793"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/611793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=611793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=611793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=611793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}